Marion Hardtke
Bayer (Germany)(DE)
Publications by Year
Research Areas
Hemophilia Treatment and Research, Platelet Disorders and Treatments, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Menopause: Health Impacts and Treatments, Maternal Mental Health During Pregnancy and Postpartum
Most-Cited Works
- → Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII(2016)116 cited
- → TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity(2016)28 cited
- → The TRUST Trial: Anti-Drug Antibody Formation In a Patient With Hemophilia With Inhibitors After Receiving The Activated Factor VII Product Bay 86-6150(2013)11 cited
- → Hormone withdrawal-associated symptoms with ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 µg/desogestrel 150 µg (21/7 regimen)(2015)8 cited
- → Mapping T-Cell Peptide Epitopes on Activated Recombinant Factor VII (rFVIIa) Contributing to Inhibitor Antibody Response(2015)